Scinovex
article Open AccessTop 10% cited

SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation

The Journal of Immunology · 2004 · Vol. 173(2) · pp. 945–954
Jens M. ChemnitzRichard V. ParryKim E. NicholsCarl H. JuneJames L. Riley

Abstract

To study the cis- and trans-acting factors that mediate programmed death 1 (PD-1) signaling in primary human CD4 T cells, we constructed a chimeric molecule consisting of the murine CD28 extracellular domain and human PD-1 cytoplasmic tail. When introduced into CD4 T cells, this construct mimics the activity of endogenous PD-1 in terms of its ability to suppress T cell expansion and cytokine production. The cytoplasmic tail of PD-1 contains two structural motifs, an ITIM and an immunoreceptor tyrosine-based switch motif (ITSM). Mutation of the ITIM had little effect on PD-1 signaling or functional activity. In contrast, mutation of the ITSM abrogated the ability of PD-1 to block cytokine synthesis and to limit T cell expansion. Further biochemical analyses revealed that the ability of PD-1 to block T cell activation correlated with recruitment of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and SHP-2, and not the adaptor Src homology 2 domain-containing molecule 1A, to the ITSM domain. In TCR-stimulated T cells, SHP-2 associated with PD-1, even in the absence of PD-1 engagement. Despite this interaction, the ability of PD-1 to block T cell activation required receptor ligation, suggesting that colocalization of PD-1 with CD3 and/or CD28 may be necessary for inhibition of T cell activation.

T-cell and B-cell ImmunologyImmune Cell Function and InteractionCancer Immunotherapy and BiomarkersImmunoreceptor tyrosine-based activation motifCD28Cell biologyT-cell receptorProto-oncogene tyrosine-protein kinase SrcProtein tyrosine phosphataseT cellSH2 domainBiologyJurkat cells

MeSH terms

Antigens, SurfaceHumansReceptors, ImmunologicRecombinant Fusion ProteinsT-LymphocytesTyrosineAntigens, CDProtein Tyrosine PhosphatasesApoptosisCD28 AntigensIntracellular Signaling Peptides and ProteinsApoptosis Regulatory ProteinsProtein Tyrosine Phosphatase, Non-Receptor Type 6Protein Tyrosine Phosphatase, Non-Receptor Type 11Protein Phosphatase 1
Citations
1,218
FWCI
6.78
field-weighted impact
References
58
Percentile
98%
vs. same field & year
Citations per year
Cited by
Immune checkpoints and their inhibition in cancer and infectious diseases
European Journal of Immunology · 2017 · 533 citations
PD-1 and Its Ligands in Tolerance and Immunity
Annual Review of Immunology · 2008 · 5,272 citations
T Cell Activation
Annual Review of Immunology · 2009 · 2,064 citations
<scp>LAG</scp>3 (<scp>CD</scp>223) as a cancer immunotherapy target
Immunological Reviews · 2017 · 946 citations
Role of the PD-1 Pathway in the Immune Response
American Journal of Transplantation · 2012 · 427 citations
THE B7 FAMILY REVISITED
Annual Review of Immunology · 2005 · 2,279 citations
Oncotarget
Oncotarget · 2016 · 381 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.